drugset / Trial / NCT06364852
An Evaluation of LY007 Cell Injection for r/r B-NHL
Phase 1
Unknown
18 enrolled
Ruijin Hospital
Shanghai Longyao Biotechnology Inc., Ltd. · collabThe First Affiliated Hospital with Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research
Timeline
- Start
- 2021-12-25
- Primary completion
- 2024-08-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY007 | Cell therapy | — | — |